Polycystic ovary syndrome and chronic inflammation: Pharmacotherapeutic implications;Síndrome ovárico poliquístico e inflamación crónica: Implicaciones farmacoterapéuticas

Annals of Pharmacotherapy

Volumn 46, Issue 3, 2012, Pages 403-418

  Sirmans, Susan Maureen ^a   Weidman Evans, Emily ^a,b   Everton, Victoria ^b   Thompson, Daniel ^b  

^a UNIVERSITY OF LOUISIANA   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Cardiovasular disease; Inflammation; Polycystic ovary syndrome

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ATORVASTATIN; CYPROTERONE ACETATE; ETHINYLESTRADIOL; FOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN SENSITIZING AGENT; LEVONORGESTREL; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SIMVASTATIN; SPIRONOLACTONE; TROGLITAZONE;

ARTICLE; BODY FAT DISTRIBUTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; DIABETES MELLITUS; DYSLIPIDEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; MEDLINE; METABOLIC SYNDROME X; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL;

CARDIOVASCULAR DISEASES; CHRONIC DISEASE; FEMALE; HUMANS; INFLAMMATION; POLYCYSTIC OVARY SYNDROME; RISK FACTORS;

EID: 84858111974     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q514     Document Type: Article

References (150)

1. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000;85:2434-8. DOI 10.1210/jc.85.7.2434
2. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999;84:4006-11. DOI 10.1210/jc.84.11.4006
3. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yilddiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745-9. DOI 10.1210/jc.2003-032046
4. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998;83:3078-82. DOI 10.1210/jc.83.9.3078
5. Alvarez-Blasco F, Botella-Carretero JI, San Millan JL, Escobar-Morreale H. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch Intern Med 2006;166:2081-6.
6. Li Y, Li Y, Yu Ng EH, et al. Polycystic ovary syndrome is associated with negatively variable impacts on domains of health-related quality of life: evidence from a meta-analysis. Fertil Steril 2011;96:452-8. DOI 10.1016/j.fertnstert.2011.05.072
7. Azziz R, Marin C, Hoq L, Badamgarav E, Song P. Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. J Clin Endocrinol Metab 2005;90:4650-8. DOI 10.1210/jc.2005-0628
8. Zawadski J, Dunaif A. Diagnostic criteria for polycystic ovary syndrome. In: Givens J, Merriman G, eds. The polycystic ovary syndrome. Cambridge, MA: Blackwell Scientific, 1992:377-84.
9. Group TREA-SPCW. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25. DOI 10.1093/humrep/deh098
10. Azziz R, Carmina E, DeWailly D, et al. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006;91:4237-45. DOI 10.1210/jc.2006-0178
11. Kirchengast S, Huber J. Body composition characteristics and fat distri- bution patterns in young infertile women. Fertil Steril 2004;81:539-544. DOI 10.1016/j.fertnstert.2003.08.018
12. Carmina E, Bucchieri S, Esposito A, et al. Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance. J Clin Endocrinol Metab 2007;92:2500-5. DOI 10.1210/jc.2006-2725
13. Yildrim B, Sabir N, Kaleli B. Relation of intra-abdominal fat distribution to metabolic disorders in nonobese patients with polycystic ovary syndrome. Fertil Steril 2003;79:2003. DOI 10.1016/S0015-0282(03)00265-6
14. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 af- fected women. J Clin Endocrinol Metab 1999;84:165-169. DOI 10.1210/jc.84.1.165
15. Norman RJ, Masters L, Milner CR, Wang JX, Davies MJ. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod 2001;16:1995-8. DOI 10.1093/humrep/16.9.1995
16. Lo JC, Feigenbaum SL, Yand J, Pressman AR, Selby JV, Go AS. Epidemiology and adverse cardiovascular risk profile of diagnosed polycys- tic ovary syndrome. J Clin Endocrinol Metab 2006;91:1357-63. DOI 10.1210/jc.2005-2430
17. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 2001;111:607-13. DOI 10.1016/S0002-9343(01)00948-2
18. Westerveld H, Hoogendoorn M polycystic ovary syndrome: pharmacotherapeutic insights Pharmacol Ther 2008;119:223-41. DOI 10.1016/j.pharmthera.2008.04.009
19. Elting MW, Korsen TJM, Bezemer PD, Schoemaker J. Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of Dutch PCOS population. Hum Reprod 2001;16:556-60. DOI 10.1093/humrep/16.3.556
20. Dahlgren E, Janson PO, Johansson S. Polycystic ovary syndrome and risk for myocardial infarction. Acta Obstet Gynecol Scand 1992;71:599-604. DOI 10.3109/00016349209006227
21. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22:141-6. DOI 10.2337/diacare.22.1.141
22. Palmert MR, Gordon CM, Kartashov AI, Legro RS, Emans SJ, Dunaif A. Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:1017-23. DOI 10.1210/jc.87.3.1017
23. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocrin Rev 1997;18:774-800. DOI 10.1210/er.18.6.774
24. Carmina E, Lobo R. Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. Fertil Steril 2004;82:661-5. DOI 10.1016/j.fertnstert.2004.01.041
25. Schachter M, Raziel A, Friedler S, Strassburger D, Bern O, Ron-El R. Insulin resistance in patients with polycystic ovary syndrome is associated with elevated plasma homocysteine. Hum Reprod 2003;18:721-7. DOI 10.1093/humrep/deg190
26. Ovalle F, Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril 2002;77:1095-105. DOI 10.1016/S0015-0282(02)03111-4
27. Yildiz BO, Haznedaroglu IC, Kirazli S, Bayraktar M. Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state. J Clin Endocrinol Metab 2002;87:3871-5. DOI 10.1210/jc.87.8.3871
28. Dunaif A, Sega KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165-74. DOI 10.2337/diabetes.38.9.1165
29. Hoeger KM. Obesity and lifestyle management in polycystic ovary syndrome. Clin Obstet Gynecol 2007;50:277-94. DOI 10.1097/GRF.0b013e31802f54c8
30. Arslanian SA, Lewy VD, Danadian K. Glucose intolerance in obese adolescents with polycystic ovary syndrome: roles of insulin resistance and beta cell dysfunction and risk of cardiovascular disease. J Clin En- docrinol Metab 2001;86:66-71. DOI 10.1210/jc.86.1.66
31. O'Meara NM, Blackman JD, Erhman DA. Defects in B-cell function and insulin action in functional ovarian hyperandrogenism. J Clin Endocrinol Metab 1993;76:1241-7. DOI 10.1210/jc.76.5.1241
32. Ehrmann D, Sturis J, Byrne M, Karrison T, Rosenfield R, Polonsky K. Insulin secretory defects in polycystic ovary syndrome: relationship to insulin sensitivity and family history of non-insulin dependent diabetes mellitus. J Clin Invest 1995;96:520-7. DOI 10.1172/JCI118064
33. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syn- drome. J Clin Endocrinol Metab 2005;90:1929-35. DOI 10.1210/jc.2004-1045
34. Coviello AD, Legro RS, Dunaif A. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab 2006;91:492-7. DOI 10.1210/jc.2005-1666
35. Balen A, Conway G, Kaltsas G. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod 1995;10:2107-11.
36. Conway GS, Honour JW, Jacobs HS. Heterogeneity of the polycystic ovary syndrome: clinical, endocrine and ultrasound features in 556 pa- tients. Clin Endocrinol (Oxf) 1989;30:459-70. DOI 10.1111/j.1365-2265.1989.tb00446.x
37. Andersen P, Seljeflot I, Abdelnoor M, et al. Increased insulin sensitivity and fibrinolytic capicity after dietary intervention in obese women with polycystic ovary syndrome. Metabolism 1995;44:611-6. DOI 10.1016/0026-0495(95)90118-3
38. Moran LJ, Noakes M, Clifton PM, Tomlinson L, Norman RJ. Dietary composition in restoring reproductive and metabolic physiology in over- weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:812-9. DOI 10.1210/jc.2002-020815
39. Huber-Buchholz MM, Carey D, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 1999;84:1470-4. DOI 10.1210/jc.84.4.1470
40. Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 2000;52:595-600. DOI 10.1046/j.1365-2265.2000.01000.x
41. Shaw LJ, Bairey Merz CN, Azziz R, et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the Na- tional Institutes of Health-National Heart, Lung, and Blood Institute Sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 2008;93:1276-84. DOI 10.1210/jc.2007-0425
42. Solomon CG, Hu FB, Dunaif A, et al. Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab 2002; 87:2013-7. DOI 10.1210/jc.87.5.2013
43. Arad Y, Spadaro LA, Goodman K, Newstein D, Guerci AD. Prediction of coronary events with electron beam computed tomography. J Am Coll Cardiol 2000;36:1253-60. DOI 10.1016/S0735-1097(00)00872-X
44. Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy PF, Fitzpatrick LA. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88:2562-8. DOI 10.1210/jc.2003-030334
45. Talbott EO, Zborowski JV, Rager JR, Boudreaux MY, Edmundowicz DA, Guzick DS. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89: 5454-61. DOI 10.1210/jc.2003-032237
46. Shroff R, Kerchner A, Maifeld M, Van Beek E, Jagasia D, Dokras A. Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis. J Clin Endocrinol Metab 2007;92:4609-14. DOI 10.1210/jc.2007-1343
47. Talbott EO, Zborowski JV, Rager J, Stragand JR. Is there an independent effect of polycystic ovary syndrome (PCOS) and menopause on the prevalence of subclinical atherosclerosis in middle aged women? Vasc Health Risk Manag 2008;4:453-62. DOI http://dx.doi.org/10.2147/VHRM.S1452
48. Guzick DS, Talbot EO, Sutton-Tyrrell K. Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study. Am J Obstet Gynecol 1996;174:1224-32. DOI 10.1016/S0002-9378(96)70665-8
49. Carmina E, Orio F, Palomba S, et al. Endothelial dysfunction in PCOS: role of obesity and adipose hormones. Am J Med 2006;119:356.e351-6. DOI 10.1016/j.amjmed.2005.10.059
50. Vryonidou A, Papatheodorou A, Tavridou A, et al. Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome. J Clin En- docrinol Metab 2005;90:2740-6. DOI 10.1210/jc.2004-2363
51. Orio Jr. F, Palomba S, Cascella T, et al. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:4588-93. DOI 10.1210/jc.2003-031867
52. Cascella T, Palomba S, Tauchmanova L, et al. Serum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2006;91:4395-400. DOI 10.1210/jc.2006-0399
53. Orio F, Palomba S, Spinelli L, et al. The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J Clin Endocrinol Metab 2004;89:3696-701. DOI 10.1210/jc.2003-032049
54. Celik O, Sahin I, Celik N, et al. Diagnostic potential of serum N-terminal pro-B-type brain natriuretic peptide level in detection of cardiac wall stress in women with polycystic ovary syndrome: a cross-sectional comparison study. Hum Reprod 2007;22:2992-8. DOI 10.1093/humrep/dem286
55. Yarali H, Yildirir A, Abybar F, et al. Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardio- vascular risk in patients with polycystic ovary syndrome. Fertil Steril 2001;76:511-6. DOI 10.1016/S0015-0282(01)01937-9
56. Kravariti M, Naka KK, Kalantaridou SN, et al. Predictors of endothelial dysfunction in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:5088-95. DOI 10.1210/jc.2005-0151
57. Alexandraki K, Protogerou A, Papaioannou TG, et al. Early microvascular and macrovascular dysfunction is not accompanied by structural arterial in- jury in polycystic ovary syndrome. Hormones (Athens) 2006;5:126-36.
58. Diamanti-Kandarakis E, Alexandraki K, Piperi C, et al. Inflammatory and endothelial markers in women with polycystic ovary syndrome. Eur J Clin Invest 2006;36:691-7. DOI 10.1111/j.1365-2362.2006.01712.x
59. Lakhani K, Leonard A, Seifalian AM, Hardiman P. Microvascular dys- function in women with polycystic ovary syndrome. Hum Reprod 2005;20:3219-24. DOI 10.1093/humrep/dei199
60. Sorensen MB, Franks S, Robertson C, Pennell DJ, Collins P. Severe en- dothelial dysfunction in young women with polycystic ovary syndrome is only partially explained by known cardiovascular risk factors. Clin En- docrinol (Oxf) 2006;65:655-9. DOI 10.1111/j.1365-2265.2006.02645.x
61. Tarkun I, Arslan BC, Canturk Z, Turemen E, Sahin T, Duman C. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab 2004;89:5592-6. DOI 10.1210/jc.2004-0751
62. Lowenstein L, Damti A, Pillar G, Shott S, Blumenfeld Z. Evaluation of endothelial function in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2007;134:203-12. DOI10.1016/j.ejogrb.2007.02.011
63. Paradisi G, Steinberg HO, Hempfling A, et al. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 2001;103: 1410-5. DOI 10.1161/01.CIR.103.10.1410
64. Mather K, Verma S, Corenblum B, Anderson TJ. Normal endothelial function despite insulin resistance in healthy women with polycystic ovary syndrome. J Clin Endocrinol Metab 2000;85:1851-6. DOI 10.1210/jc.85.5.1851
65. Beckman JA, Goldfine AB, Dunaif A, Gerhard-Herman M, Creager MA. Endothelial function varies according to insulin resistance disease type. Diabetes Care 2007;30:1226-32. DOI 10.2337/dc06-2142
66. Brinkworth GD, Noakes M, Moran LJ, Norman R, Clifton PM. Flow-mediated dilation in over weight and obese women with polycystic ovary syndrome. BJOG 2006;113:1308-14. DOI 10.1111/j.1471-0528.2006.01090.x
67. Dokras A, Jagasia D, Maifeld M, Sinkey CA, Van Voorhis BJ, Hayes WG. Obesity and insulin resistance but not hyperandrogenism mediates vascular dysfunction in women with polycystic ovary syndrome. Fertil Steril 2006;86:1702-9. DOI 10.1016/j.fertnstert.2006.05.038
68. Haensel A, Mills PJ, Nelesen RA, Ziegler MG, Dimsdale JE. The rela- tionship between heart rate variability and inflammatory markers in car- diovascular diseases. Psychoneuroendocrinology 2008;33:1305-12. DOI10.1016/j.psyneuen.2008.08.007
69. Gulick T, Chung MK, Pieper SJ, Lange LG, Schreiner GF. Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness. Proc Natl Acad Sci U S A 1989;86:6753-67.
70. Muller-Werdan U, Schumann H, Fuchs R, et al. Tumor necrosis factor alpha (TNF alpha) is cardiodepressant in pathophysiologically relevant concentrations without inducing inducible nitric oxide-(NO)-synthase (iNOS) or triggering serious cytotoxicity. J Mol Cell Cardiol 1997;29: 2915-23. DOI 10.1006/jmcc.1997.0526
71. Ishikawa C, Tsutamoto T, Fujii M, Sakai H, Tanaka T, Horie M. Prediction of mortality by high-sensitivity C-reactive protein and brain natriuretic peptide in patients with dilated cardiomyopathy. Circ J 2006;70: 857-63. DOI 10.1253/circj.70.857
72. Rosen BD, Cushman M, Nasir K, et al. Relationship between C-reactive protein levels and regional left ventricular function in asymptomatic individuals: the Multi-Ethnic Study of Atherosclerosis. J Am Coll Cardiol 2007;49:594-600. DOI 10.1016/j.jacc.2006.09.040
73. Bujak M, Frangogiannis N. The role of IL-1 in the pathogenesis of heart disease. Archivum Immunologiae et Therapiae Experimentalis 2009;57: 165-76. DOI 10.1007/s00005-009-0024-y
74. Walch K, Grimm C, Zeillinger R, Huber JC, Nagele F, Hefler LA. A common interleukin-6 gene promoter polymorphism influences the clinical characteristics of women with polycystic ovary syndrome. Fertil Ster- il 2004;81:1638-41. DOI 10.1016/j.fertnstert.2004.01.021
75. Parish RC, Evans JD. Inflammation in Chronic Heart Failure Ann Pharmacother 2008;42:1002-16. DOI 10.1345/aph.1K272
76. Ridker PM. Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. Nutr Rev 2007;65(12 pt 2):S253-9. DOI 10.1111/j.1753-4887.2007.tb00372.x
77. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43. DOI 10.1056/NEJM200003233421202
78. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000;101:2149-53. DOI 10.1161/01.CIR.101.18.2149
79. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000;101:1767-2. DOI 10.1161/01.CIR.101.15.1767
80. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001;285:2481-5. DOI 10.1001/jama.285.19.2481
81. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2008;107:868-9. DOI 10.1161/01.CIR.0000053730.47739.3C
82. van Leuven SI, Franssen R, Kastelein JJ, Levi M, Stroes ES, Tak PP. Systemic inflammation as a risk factor for atherothrombosis. Rheumatology (Oxford) 2008;47:3-7. DOI 10.1093/rheumatology/kem202
83. Greenfield JR, Campbell LV. Relationship between inflammation, insulin resistance and type 2 diabetes: cause or effect? Curr Diabetes Rev 2006;2:195-211. DOI 10.2337/db08-1656
84. Levi M, Neiuwdorp M, van der Poll TES. Metabolic modulation of inflammation-induced activation of coagulation. Semin Thromb Hemost 2008;34:26-32. DOI 10.1055/s-2008-1066020
85. Pradhan A. Obesity, metabolic syndrome, and type 2 diabetes: inflammatory basis of glucose metabolic disorders. Nutr Rev 2007;65:152-6. DOI 10.1111/j.1753- 4887.2007.tb00354.x
86. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340:115-26. DOI 10.1056/NEJM199901143400207
87. Arikan S, Akay H, Bahceci M, Tuzcu A, Gokalp D. The evaluation of endothelial function with flow-mediated dilatation and carotid intima media thickness in young nonobese polycystic ovary syndrome patients; existence of insulin resistance alone may not represent an adequate con- dition for deterioration of endothelial function. Fertil Steril 2008;90:450-455. DOI 10.1016/j.fertnstert.2008.12.105
88. Bickerton AS, Clark N, Meeking D, et al. Cardiovascular risk in women with polycystic ovarian syndrome (PCOS). J Clin Pathol 2005;58: 151-4. DOI 10.1136/jcp.2003.015271
89. Escobar-Morreale HF, Villuendas G, Botella-Carretero JI, Sancho J, San Millan JL. Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women. Diabetologia 2003;46:625-33. DOI 10.1007/s00125-003-1090-z
90. Benson S, Janssen OE, Hahn S, et al. Obesity, depression, and chronic low-grade inflammation in women with polycystic ovary syndrome. Brain Behav Immun 2008;22:177-84. DOI 10.1016/j.bbi.2007.07.003
91. Carmassi F, De Negri F, Fioriti R, et al. Insulin resistance causes impaired vasodilation and hypofibrinolysis in young women with polycys- tic ovary syndrome. Thromb Res 2005;116:207-14. DOI 10.1016/j.thromres.2004.11.026
92. Diamanti-Kandarakis E, Paterakis T, Alexandraki K, et al. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod 2006;21:1426-31. DOI 10.1093/humrep/del003
93. Glintborg D, Hojlund K, Andersen M, Henriksen JE, Beck-Nielsen H, Handberg A. Soluble CD 36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and signifi- cantly reduced during pioglitazone treatment. Diabetes Care 2008;31: 328-34. DOI 10.2337/dc07-1424
94. Orio F Jr, Palomba S, Cascella T, et al. The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:2-5. DOI 10.1210/jc.2004-0628
95. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001;86:2453-5. DOI 10.1210/jc.86.6.2453
96. Mohlig M, Spranger J, Osterhoff M, et al. The polycystic ovary syndrome per se is not associated with increased chronic inflammation. Eur J Endocrinol 2004;150:525-32. DOI 10.1530/eje.0.1500525
97. Puder JJ, Varga S, Kraenzlin M, De Geyter C, Keller U, Muller B. Central fat excess in polycystic ovary syndrome: relation to low-grade in- flammation and insulin resistance. J Clin Endocrinol Metab 2005;90: 6014-21. DOI 10.1210/jc.2005-1002
98. Sharon J. Basic Immunology. Baltimore: Williams and Wilkins, 1998.
99. Kelly CJG, Lyall H, Petrie JR, et al. A specific elevation in tissue plasminogen activator antigen in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2002;87:3287-90. DOI 10.1210/jc.87.7.3287
100. Dereli D, Ozgen G, Buyukkececi F, Guney E, Yilmaz C. Platelet dysfunction in lean women with polycystic ovary syndrome and associa- tion with insulin sensitivity. J Clin Endocrinol Metab 2003;88:2263-8. DOI 10.1210/jc.2002-021391
101. Carmina E, Orio F, Palomba S, et al. Endothelial dysfunction in PCOS: role of obesity and adipose hormones. Am J Med 2006;119:356.e351-6. DOI 10.1016/j.amjmed.2005.10.059
102. Orio F Jr, Palomba S, Cascella T, et al. Adiponectin levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88: 2619-23. DOI 10.1210/jc.2002-02203
103. Panidis D, Kourtis A, Farmakiotis D, Mouslech T, Rousso D, Koliakos G. Serum adiponectin levels in women with polycystic ovary syndrome. Hum Reprod 2003;18:1790-6. DOI 10.1093/humrep/deg353
104. Spranger J, Möhlig M, Wegewitz U, et al. Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syn- drome. Clin Endocrinol (Oxf) 2004;61:738-46. DOI 10.1111/j.1365-2265.2004.02159.x
105. Carmina E, Orio F, Palomba S, et al. Evidence for altered adipocyte function in polycystic ovary syndrome. Eur J Endocrinol 2005;152:389-94. DOI 10.1530/eje.1.01868
106. Chapman IM, Wittert GA, Norman RJ. Circulating leptin concentra- tions in polycystic ovary syndrome: relation to anthropometric and metabolic parameters. Clin Endocrinol (Oxf) 1997;46:175-81. DOI 10.1046/j.1365-2265.1997.1200936.x
107. Erturk E, Kuru N, Savci V, Tuncel E, Ersoy C, Imamoglu S. Serum lep- tin levels correlate with obesity parameters but not with hyperinsulinism in women with polycystic ovary syndrome. Fertil Steril 2004;82:1364-8. DOI 10.1016/j.fertnstert.2004.04.049
108. Panidis D, Koliakos G, Kourtis A, Farmakiotis D, Mouslech T, Rousso D. Serum resistin levels in women with polycystic ovary syndrome. Fertil Steril 2004;81:361-6.=DOI 10.1016/j.fertnstert.2003.06.021
109. Saleh HA, El-Nwaem MA, El-Bordiny MM, Maqlad HM, El-Mohandes AA, Eldaqaq EM. Serum leptin elevation in obese women with PCOs: a continuing controversy. J Assist Reprod Genet 2004;21:361-6. DOI 10.1023/B:JARG.0000046204.81682.67
110. Seow K-M, Juan C-C, Wu L-Y, et al. Serum and adipocyte resistin in polycystic ovary syndrome with insulin resistance. Hum Reprod 2004; 19:48-53. DOI 10.1093/humrep/deh010
111. Telli MH, Yildirim M, Noyan V. Serum leptin levels in patients with polycystic ovary syndrome. Fertil Steril 2002;77:932-5. DOI 10.1016/S0015-0282(02)02995-3
112. Hukshorn CJ, Lindeman JHN, Toet KH, et al. Leptin and the proinflammatory state associated with human obesity. J Clin Endocrinol Metab 2004;89:1773-8. DOI 10.1210/jc.2003-030803
113. van Dielen FM, van't Veer C, Schols AM, Soeters PB, Buurman WA, Greve JW. Increased leptin concentrations correlate with increased concentrations of inflammatory markers in morbidly obese individuals. Int J Obes Relat Metab Disord 2001;25:1759-66. DOI 10.1038/sj.ijo.0801825
114. Kolbus A, Walch K, Nagele F, Wenzl R, Unfried G, Huber JC. Interleukin-1 alpha but not interleukin-1 beta gene polymorphism is associat- ed with polycystic ovary syndrome. J Reprod Immunol 2007;73:188-93. DOI 10.1016/j.jri.2006.08.002
115. Kolbus A, Walch K, Szabo L, Huber JC, Nagele F, Unfried G. A polymorphism of the interleukin 1 receptor antagonist is not associated with polycystic ovary syndrome in Caucasian women. Fertil Steril 2006; 85:523-5. DOI 10.1016/j.fertnstert.2005.07.1317
116. Vgontzas AN, Trakada G, Bixler EO, et al. Plasma interleukin 6 levels are elevated in polycystic ovary syndrome independently of obesity or sleep apnea. Metabolism 2006;55:1076-82. DOI 10.1016/j.metabol.2006.04.002
117. Victor VM, Rocha M, Bañuls C, et al. Induction of oxidative stress and human leukocyte/endothelial cell interactions in polycystic ovary syndrome patients with insulin resistance. J Clin Endocrinol Metab 2011;96:3115-22. DOI 10.1210/jc.2011-0651
118. Escobar-Morreale HF, Botella-Carretero JI, Villuendas G, Sancho J, San Millan JL. Serum interleukin-18 concentrations are increased in the polycystic ovary syndrome: relationship to insulin resistance and to obesity. J Clin Endocrinol Metab 2004;89:806-11. DOI 10.1210/jc.2003-031365
119. Olszanecka-Glinianowicz M, Banas M, Zahorska-Markiewicz B, et al. Is the polycystic ovary syndrome associated with chronic inflammation per se? Eur J Obstet Gynecol Reprod Biol 2007;133:197-202. DOI 10.1016/j.ejogrb.2006.10.037
120. Ibanez L, Jaramillo AM, Ferrer A, de Zegher F. High neutrophil count in girls and women with hyperinsulinaemic hyperandrogenism: normalization with metformin and flutamide overcomes the aggravation by oral contraception. Hum Reprod 2005;20:2457-62. DOI10.1093/humrep/dei072
121. Repaci A, Gambineri A, Pasquali R. The role of low-grade inflamma- tion in the polycystic ovary syndrome. Mol Cell Endocrinol 2011;335: 30-41. DOI 10.1016/j.mce.2010.08.002
122. ACOG Practice Bulletin No. 108: Polycystic ovary syndrome [miscel- laneous]. Obstet Gynecol 2009;114:936-49. DOI 10.1097/AOG.0b013e3181bd12cb
123. Esposito K, Pontillo A, Di Palo C, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women. JAMA 2003;289:1799-804. DOI 10.1001/jama.289.14.1799
124. Valsamakis G, McTernan PG, Chetty R, et al. Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines. Metabolism 2004; 53:430-434. DOI10.1016/j.metabol.2003.11.022
125. Moran LJ, Noakes M, Clifton PM, et al. C-reactive protein before and after weight loss in overweight women with and without polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:2944-51. DOI 10.1210/jc.2006-2336
126. Agarwal N, Rice SPL, Bolusani H, et al. Metformin reduces arterial stiff- ness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial. J Clin Endocrinol Metab 2010;95:722-30. DOI 10.1210/jc.2009-1985
127. Palomba S, Falbo A, Giallauria F, et al. Effects of metformin with or without supplementation with folate on homocysteine levels and vascu- lar endothelium of women with polycystic ovary syndrome. Diabetes Care 2010;33:246-51. DOI 10.2337/dc09-1516
128. Bilgir O, Kebapcilar L, Taner C, et al. The effect of ethinylestradiol (EE)/cyproterone acetate (CA) and EE/CA plus metformin treatment on adhesion molecules in cases with polycystic ovary syndrome (PCOS). Intern Med 2009;48:1193-9. DOI 10.2169/internalmedicine.48.2177
129. Heutling D, Schulz H, Nickel I, et al. Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment. J Clin En- docrinol Metab 2008;93:82-90. DOI 10.1210/jc.2007-0842
130. Jakubowska J, Bohdanowicz-Pawlak A, Milewicz A, Szymczak J, Bednarek-Tupikowska G, Demissie M. Plasma cytokines in obese women with polycystic ovary syndrome, before and after metformin treatment. Gynecol Endocrinol 2008;24:378-84. DOI 10.1080/09513590802128968
131. Romualdi D, Costantini B, Selvaggi L, et al. Metformin improves en- dothelial function in normoinsulinemic PCOS patients: a new prospective. Hum Reprod 2008;23:2127-33. DOI 10.1093/humrep/den230
132. Meyer C, McGrath BP, Teede HJ. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care 2007;30:471-8. DOI 10.2337/dc06-0618
133. Orio F Jr, Manguso F, Di Biase S, et al. Metformin administration im- proves leukocyte count in women with polycystic ovary syndrome: a 6-month prospective study. Eur J Endocrinol 2007;157:69-73. DOI 10.1530/EJE-07-0133
134. Diamanti-Kandarakis E, Alexandraki K, Protogerou A, et al. Metformin administration improves endothelial function in women with polycystic ovary syndrome. Eur J Endocrinol 2005;152:749-56. DOI 10.1530/eje.1.01910
135. Orio F Jr, Palomba S, Cascella T, et al. Improvement in endothelial struc- ture and function after metformin treatment in young normal-weight wom- en with polycystic ovary syndrome: results of a 6-month study. J Clin En- docrinol Metab 2005;90:6072-6. DOI 10.1210/jc.2005-0965
136. Morin-Papunen L, Rautio K, Buokonen A, Hedberg P, Puukka M, Tapanainen JS. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:4649-54. DOI 10.1210/jc.2002-021688
137. Velazquez EM, Mendoza SG, Wang P, Glueck CJ. Metformin therapy is associated with a decrease in plasma plaminogen activator inhibitor- 1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism 1997;46:454-7. DOI 10.1016/S0026-0495(97)90066-4
138. Raja-Khan N, Kunselman AR, Hogeman CS, Stetter CM, Demers LM, Legro RS. Effects of atorvastatin on vascular function, inflammation and androgens in women with polycystic ovary syndrome: a double- blind, randomized, placebo-controlled trial. Fertil Steril 2011;95:1849-52. DOI 10.1016/j.fertnstert.2010.11.040
139. Kaya C, Pabuccu R, Cengiz SD, Dunder I. Comparison of the effects of atorvastatin and simvastatin in women with polycystic ovary syndrome: a prospective, randomized study. Exp Clin Endocrinol Diabetes 2010; 118:161-6. DOI 10.1055/s-0029-1220770
140. Sathyapalan T, Kilpatrick ES, Coady A-M, Atkin SL. The effect of ator- vastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. J Clin Endocrinol Metab 2009;94: 103-8. DOI 10.1210/jc.2008-1750
141. Banaszewska B, Pawelczyk L, Spaczynski RZ, Deluba AJ. Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. J Clin Endocrinol Metab 2009;94: 4938-45. DOI 10.1210/jc.2009-1674
142. Banaszewska B, Pawelczyk L, Spaczynski RZ, Dziura J, Deleba AJ. Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. J Clin Endocrinol Metab 2007;92:456-61. DOI 10.1210/jc.2006-1988
143. Jensterle M, Sebestjen M, Janez A, et al. Improvement of endothelial function with metformin and rosiglitazone treatment in women with polycystic ovary syndrome. Eur J Endocrinol 2008;159:399-406. DOI 10.1530/EJE-08-0507
144. Majuri A, Santaniemi M, Rauto K, et al. Rosiglitazone treatment in- creases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study. Eur J Endocrinol 2007;156:263-9. DOI 10.1530/eje.1.02331
145. Tarkun I, Cetinarslan B, Turemen E, Sahin T, Canturk Z, Komsuoglu B. Effect of rosiglitazone on insulin resistance, C-reactive protein and en- dothelial function in non-obese young women with polycystic ovary syn- drome. Eur J Endocrinol 2005;153:115-21. DOI 10.1530/eje.1.01948
146. Paradisi G, Steinberg HO, Shepard MK, Hook G, Baron AD. Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:576-80. DOI 10.1210/jc.2002-020386
147. Ehrmann DA, Schneider DJ, Sobel BE, et al. Troglitazone improves de- fects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin En- docrinol Metab 1997;82:2108-16. DOI 10.1210/jc.82.7.2108
148. Vague P, Juhan-Vague I, Alessi M, Badier C, Valadier J. Metformin decreases the high plasminogen activator inhibition capacity, plasma in- sulin and triglyceride levels in non-diabetic obese subjects. Thromb Haemost 1987;57:326-8.
149. Grant P, Stickland M, Booth N, Prentice C. Metformin causes a reduc- tion in basal and post-venous occlusion plasminogen activator inhibitor- 1 in type 2 diabetic patients. Diabet Med 1991;8:361-5. DOI 10.1111/j.1464-5491.1991.tb01610.x
150. Refuerzo JS. Oral hypoglycemic agents in pregnancy. Obstet Gynecol Clin North Am 2011;38:227-34. DOI10.1016/j.ogc.2011.02.